Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
26th January 2021 | Inc. Innoviva, | 1,867,912 | Open or private purchase | $3.25 | $6,070,714.00 |
15th January 2021 | Manoussos Perros | 79,750 | Grant/award etc. | $0.00 | |
15th January 2021 | Matthew Ronsheim | 25,000 | Grant/award etc. | $0.00 | |
15th January 2021 | John Patrick Mueller | 25,000 | Grant/award etc. | $0.00 | |
15th January 2021 | Elizabeth M Keiley | 25,000 | Grant/award etc. | $0.00 | |
15th January 2021 | David Altarac | 25,000 | Grant/award etc. | $0.00 | |
1st September 2020 | Inc. Innoviva, | 4,672,897 | Open or private purchase | $2.68 | $12,499,999.48 |
11th June 2020 | Inc. Innoviva, | 12,677,490 | Open or private purchase | $2.50 | $31,693,725.00 |
27th March 2020 | Inc. Innoviva, | 7,717,661 | Open or private purchase | $2.87 | $22,149,687.07 |
4th February 2020 | Life Sciences Viii, L.P. Frazier | 6,360,272 | Conversion of derivative | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.